
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics has demonstrated strong revenue momentum, with its Integrity product line projected to achieve over 100% growth in revenue from 2024 to 2025, reflecting robust market demand. Additionally, the company reported a 13% increase in international osteoarthritis pain revenue in the first quarter, indicating solid performance in a key therapeutic area. Furthermore, the regenerative solutions segment has exhibited significant growth, recording a remarkable 41% increase in the recent quarter, largely attributed to the successful adoption of the Integrity patch.
Bears say
Anika Therapeutics reported a revenue of $28.2 million, reflecting an 8.2% decline compared to the same period last year when adjusted for recent divestitures, indicating potential challenges in maintaining growth. Furthermore, international revenue from osteoarthritis pain management decreased by 10% due to order timing and production yield issues, suggesting operational difficulties. Over the past 12-18 months, the company has faced a series of negative developments that have negatively impacted investor confidence, contributing to a detrimental outlook for the stock.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares